2011 to 2020 Saw Increase in Annual Prescription Meds Expenditures
By Elana Gotkine HealthDay Reporter
MONDAY, April 15, 2024 -- From 2011 to 2020, there was an increase in total annual prescription medication expenditures, with antimetabolic agents the most costly category, according to a study published in the April issue of Research in Social and Administrative Pharmacy.
Whanhui Chi, from the University of Houston College of Pharmacy, and colleagues calculated the total annual medication expenditures by payer categories in a cross-sectional analysis using the 2011 to 2020 Medical Expenditures Panel Survey. Expenditures were stratified by therapeutic category. Temporal trends in medication expenditures were examined.
The researchers observed an increase in total annual prescription medication expenditures from $341.49 to $473.12 billion per year from 2011 to 2020, with the most costly category being metabolic agents. Antidiabetic agents were the most costly therapeutic area among the metabolic agents, with an increasing trend seen from $27.15 to $89.17 billion during the same period. Increasing trends in antidiabetic agent expenditure were seen for Medicare, Medicaid, TRICARE/Veterans Administration/CHAMPVA, and other sources; no trend was seen for the payer categories of out-of-pocket or other government sources. Of the antidiabetic agents, insulin had the highest expenditure.
"In light of these developments, research is needed to substantiate concerns that trends in the cost of care are outpacing patients' ability to pay," coauthor Tyler J. Varisco, Ph.D.., Pharm.D., also from the University of Houston College of Pharmacy, said in a statement. "Continuing analysis is needed to help policymakers and other key stakeholders understand how changes in practice, policy, and drug marketing converge to impact total market expenditures."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States
THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...
Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening
WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...
American College of Surgeons, Oct. 19-22
The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.